CN101264301A - Chinese medicinal composition for treating esophageal cancer and preparation thereof - Google Patents

Chinese medicinal composition for treating esophageal cancer and preparation thereof Download PDF

Info

Publication number
CN101264301A
CN101264301A CN 200810106125 CN200810106125A CN101264301A CN 101264301 A CN101264301 A CN 101264301A CN 200810106125 CN200810106125 CN 200810106125 CN 200810106125 A CN200810106125 A CN 200810106125A CN 101264301 A CN101264301 A CN 101264301A
Authority
CN
China
Prior art keywords
radix
parts
medicine composition
chinese medicine
esophageal cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN 200810106125
Other languages
Chinese (zh)
Inventor
伍荣林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BEIJING TIANKE RENXIANG MEDICAL SCI-TECH Co Ltd
Original Assignee
BEIJING TIANKE RENXIANG MEDICAL SCI-TECH Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BEIJING TIANKE RENXIANG MEDICAL SCI-TECH Co Ltd filed Critical BEIJING TIANKE RENXIANG MEDICAL SCI-TECH Co Ltd
Priority to CN 200810106125 priority Critical patent/CN101264301A/en
Publication of CN101264301A publication Critical patent/CN101264301A/en
Pending legal-status Critical Current

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to a Chinese herbal medicine composition for curing esophageal cancer, comprising ginseng, fritillaria unibracteata Hsiao et K. C. Hsia, clematis root, red peony root, radix adenophorea, Turmeric Root-tuber, radix glycyrrhizae, prepared pinellia tuber, hindu lotus leaf-base, safflower, angelica sinensis, polygonatum, jujube, prepared rhizome of rehmanniae and/or medically acceptable carrier. The invention also relates to the preparation method of the Chinese herbal medicine composition. The Chinese herbal medicine composition has the functions of regulating the flow of vital energy, reducing reflux, activating blood circulation to dissipate blood stasis, eliminating dampness to reduce phlegm, nourishing heart and strengthening spleen, and is used for curing symptoms such as eating difficulty, sense of foreign body in esophagus, dyspnea and dry cough caused by esophageal cancer.

Description

A kind of Chinese medicine composition for the treatment of the esophageal carcinoma and preparation method thereof
Technical field
The present invention relates to a kind of Chinese medicine composition, specifically, relate to a kind of Chinese medicine composition for the treatment of the esophageal carcinoma and preparation method thereof.
Background technology
The esophageal carcinoma is the carcinoma that is primary in esophagus, mainly comprises scale cancer, adenocarcinoma, undifferentiated small cell carcinoma, carcinosarcoma etc.But in actual diagnosis and treatment, all cancers that betides esophagus and stomach mucosa interface then are included into the esophageal carcinoma as belonging to scale cancer, then are included into carcinoma of gastric cardia as belonging to adenocarcinoma.China's mortality rate of esophageal cancer occupies first place in the world.
The high-risk group of esophageal carcinoma morbidity mainly refers to the people of following 6 types:
(1) gastrointestinal symptom is arranged;
(2) esophageal carcinoma, gastric cancer family history are arranged;
Find when primary dcreening operation is generally investigated (3) that the mucous membrane of esophagus severe epithelial increases, or the esophagitis patient;
(4) agnogenic esophagus or gastric occult blood test positive person;
(5) smoking, smoking add drinks, long-term a large amount of edible sauerkraut, foods that go mouldy of going mouldy that ferment, the crowds of the C that is deficient in vitamin, vitamin B, carotene etc.
(6) chronic esophagitis is the high-risk group with atypical hyperplasia (particularly severe atypical hyperplasia) person.
The definite etiology unknown of the esophageal carcinoma, but environment and some carcinogen are important paathogenic factors:
(1) nitrosamine compound and mycotoxin: existing known have nearly 30 kinds of nitrosamine can bring out animal tumor.Domesticly also successfully use the esophageal carcinoma that methylbenzyl nitrosamine, musculamine acetoacetic ester nitrosamine, first penta, nitrosamine and the inferior amine recklessly of diethyl etc. bring out rat.China's investigation finds that in the grain and drinking-water of district occurred frequently, nitrate, nitrite and secondary amine content significantly increase, and are proportionate these materials the easy syncarcinogen nitrosamine of gastric with the ground esophageal carcinoma and the outgrowth prevalence of epithelium of esophagus severe.
(2) esophageal injury, esophagel disease and The food stimulation effect: esophageal injury and some esophagel disease can inspire the esophageal carcinoma.In corrosive burn of esophagus and narrow, achalasia of cardia and esophagus, diverticulum of esophagus or reflux esophagitis patient, the general crowd of the sickness rate of the esophageal carcinoma be a height.Be to cause secular chronic inflammatory disease, ulcer by inference owing to being detained in the esophagus, or chronic stimulation, and then esophageal epithelial proliferation, canceration caused at last.Epidemiological study is found, the custom that the resident of esophageal carcinoma hotspot has the very boiling hot diet of feed, tipples, eats a large amount of Fructus Piperiss, betel quid chewing or tobacco shred, and the chronic physicochemical irritation of these mucous membrane of esophagus all can cause local epithelial hyperplasia.Zoopery proves that diffusivity or focal epithelial hyperplasia may be the precancerous lesion of the esophageal carcinoma.
(3) malnutrition and trace element deficiency: taking in animal proteinum deficiency and vitamin A, B2, C shortage, is the common feature of the esophageal carcinoma high district resident diet.But big polydystrophic hotspot, the esophageal carcinoma is not occurred frequently, so this can not be a leading factor.
(4) inherited genetic factors: the morbidity of the esophageal carcinoma often shows the family clustering phenomena.The investigation that economizes in China Shanxi, Shandong, Henan etc. is found, is had positive family history person to account for 1/4~1/2.The ratio height of positive family history is arranged in the district occurred frequently, and wherein paternal line is the highest, and maternal side takes second place.
(5) fat factor: of finishing of Queensland ,Australia medical research center studies show that overweight people's esophageal carcinoma incidence rate is 6 times of the normal person of body weight.People such as (online delivering in Gut on October 11st, 2007) Whiteman have carried out a case control study based on the crowd.Patient and 1580 collators that 367 routine adenocarcinoma of esophagus patients, 426 routine adenocarcinoma betide stomach-esophagogastric junction place are included in research altogether in.Result of study shows that the initiation potential of individual adenocarcinoma of esophagus increases (P<0.001) with the increase of body weight index (BMI).BMI>40kg/m2 (OR=6.1) person, (BMI is 18.5 ~ 24.9kg/m2), and its adenocarcinoma of esophagus initiation potential is the highest with respect to the normal person of body weight.In addition, the initiation potential of male overweight person adenocarcinoma of esophagus (OR=2.6) person (OR=1.4) that is higher than the women obesity; Overweight people's initiation potential (OR=7.5) of age<50 year old is higher than the overweight people (OR=2.2) of age>50 year old.The overweight people who has the gastroesophageal reflux symptom to take place frequently, its initiation potential (OR=16.5) is significantly higher than asymptomatic overweight people (OR=2.2) or has anti-stream symptom not have overweight people (OR=5.6).Betide among the overweight people at stomach-esophagogastric junction place in adenocarcinoma, also observed similar association, but related degree is less.This studies prompting, and the danger of the individual adenocarcinoma of esophagus of fat increase itself is especially for the male.The easier trouble adenocarcinoma of esophagus of the overweight people who has the gastroesophageal reflux symptom to take place frequently.
The traditional Chinese medical science thinks that the esophageal carcinoma belongs to categories such as " dysphagic ", " regurgitation ", " obstruction and rejection ", " levying long-pending ".The generation of primary disease is many because of anxiety and rage, and feelings will is unsuccessful, seven emotions pent-up; Or it is immoderate to be addicted to drink, and throws off restraint the hot fragrant scorching thing that waits of food, and impairing the spleen and stomach causes stagnation of QI food to coagulate, and gathers in bulk; Or aging in high year, healthy energy will void, vital QI cannot conquer pathogen, the evil intrusion in an opponent's defence of tumor forms.Center " Jing Yue's complete work is dysphagic " is sayed: " a dysphagic card must be pondered over sorrow, and it is strongly fragrant to be overworked for a very long period, or indulgence in drinking and sexsual activity, and damage forms ".The Qing Dynasty cures tame Xu Ling tire and points out when commenting " Linzheng Zhinan Yi is dysphagic ": " dysphagic card must have blood stasis, pertinacious phlegm, contrary gas, intercepts gastric qi." its pathomechanism, down not following five aspects:
(1) stagnation of QI: disorder of emotion, anxiety and rage, or be satiated with food do not save, the cold and heat discomfort, cause depression and stagnation of QI, gas is cloth Tianjin not, body fluid is poly-and be that expectorant, mental disorder hand over the resistance esophagus to form.
(2) blood stasis: disorder of emotion, depression and stagnation of QI causes hematogenous blockage, qi depression to blood stasis, phlegm-damp is not changed, and expectorant coagulates hands over knot, gathers to form.
(3) expectorant coagulates: feelings will is disgruntled, and the drink letter does not save, impairing the spleen and stomach, and water-damp not being transformed poly-ly wetly is expectorant, or it is immoderate to be addicted to drink, the hobby delicious food, it is turbid to lead to expectorant, and expectorant coagulates fuse tube, forms lump.
(4) pyretic toxicity: indulgence in drinking and sexsual activity, damaged by excess of seven emotions is wrongly taken hot dry medicine, all makes Tianjin anemia void, and fire is gradually vehement mutually, with the passing of time becomes poison, the esophagus of burning to form.
(5) weakened body resistance: the natural endowment deficiency, or the gas affair is big, and high year is old and feeble, disorder of YIN and YANG, the extreme misery imbalance, vital QI cannot conquer pathogen, the tumor heresy is taken advantage of a weak point in opponent's defence to invade and is formed.
The traditional Chinese medical science adopts this disease of decoction for the treatment of regulating QI and lowering the adverseness, blood circulation promoting and blood stasis dispelling, drying dampness to eliminate phlegm, the spleen invigorating of nourishing heart.
Summary of the invention
The purpose of this invention is to provide a kind of Chinese medicine composition for the treatment of the esophageal carcinoma.
The present invention also aims to provide a kind of preparation method of this Chinese medicine composition.
In order to realize purpose of the present invention, the invention provides a kind of Chinese medicine composition for the treatment of the esophageal carcinoma, be to make by effective ingredient and/or pharmaceutically acceptable carrier, described effective ingredient is made by weight by following raw materials according:
Radix Ginseng 5-10 part Bulbus Fritillariae Cirrhosae 10-20 part Radix Clematidis 15-20 part
Radix Paeoniae Rubra 10-20 part Radix Adenophorae (Radix Glehniae) 15-25 part Radix Curcumae 10-15 part
Radix Glycyrrhizae 20-30 part Rhizoma Pinelliae Preparatum 15-25 part Folium Nelumbinis Basis 10-20 part
Flos Carthami 15-20 part Radix Angelicae Sinensis 5-10 part Rhizoma Polygonati Odorati 10-20 part
Fructus Jujubae 15-25 part Radix Rehmanniae Preparata 10-20 part
Effective ingredient is preferably made by weight by following raw materials according:
18 parts of 16 parts of Radix Clematidis of 8 parts of Bulbus Fritillariae Cirrhosae of Radix Ginseng
13 parts of 21 portions of Radix Curcumaes of 16 parts of Radix Adenophorae (Radix Glehniae) of Radix Paeoniae Rubra
16 parts of 20 parts of Folium Nelumbinis Basiss of 26 parts of Rhizoma Pinelliae Preparatum of Radix Glycyrrhizae
16 parts of 8 portions of Rhizoma Polygonati Odorati of 18 parts of Radix Angelicae Sinensis of Flos Carthami
16 parts in 21 parts of Radix Rehmanniaes Preparata of Fructus Jujubae
The present invention also provides a kind of preparation method of this Chinese medicine composition, comprises the steps:
(1) to be broken into impalpable powder standby for Radix Angelicae Sinensis powder;
(2) Bulbus Fritillariae Cirrhosae, Radix Glycyrrhizae, Flos Carthami, Radix Ginseng, Radix Clematidis, Radix Paeoniae Rubra, Radix Adenophorae (Radix Glehniae), Radix Curcumae, Rhizoma Pinelliae Preparatum, Folium Nelumbinis Basis, Rhizoma Polygonati Odorati, Fructus Jujubae, Radix Rehmanniae Preparata decoct with water secondary, each 2 hours, filter, merging filtrate left standstill 48 hours, get supernatant, it is the thick paste of 1.20 (60 ℃) that concentrating under reduced pressure becomes relative density, adds above-mentioned fine powder, drying, be ground into fine powder, make granule, capsule and tablet with pharmaceutically acceptable carrier.
Chinese medicine composition of the present invention can with receivable carrier pharmaceutically, for example: filler such as starch, microcrystalline Cellulose etc.; Binding agent such as vitamin derivative, starch etc.; Mode by granule, capsule, tablet oral administration is used.
Chinese medicine composition of the present invention has effects such as regulating QI and lowering the adverseness, blood circulation promoting and blood stasis dispelling, drying dampness to eliminate phlegm, the spleen invigorating of nourishing heart, and is used for diseases such as foreign body sensation in hypopharynx difficulty that the esophageal carcinoma causes, the esophagus, out of breath or dry cough.
The specific embodiment
Following examples are used to illustrate the present invention, but are not used for limiting the scope of the invention.
Embodiment 1: Chinese medicinal composition granules of the present invention
(1) Radix Angelicae Sinensis 80g is ground into impalpable powder, and is standby;
(2) Bulbus Fritillariae Cirrhosae 160g, Radix Glycyrrhizae 260g, Flos Carthami 180g, Radix Ginseng 80g, Radix Clematidis 180g, Radix Paeoniae Rubra 160g, Radix Adenophorae (Radix Glehniae) 210g, Radix Curcumae 130g, Rhizoma Pinelliae Preparatum 200g, Folium Nelumbinis Basis 160g, Rhizoma Polygonati Odorati 160g, Fructus Jujubae 210g, Radix Rehmanniae Preparata 160g decoct with water secondary, each 2 hours, filter, merging filtrate, left standstill 48 hours, and got supernatant, it is the thick paste of 1.20 (60 ℃) that concentrating under reduced pressure becomes relative density, add above-mentioned fine powder, drying is ground into fine powder, adds lactose 400g, dextrin 800g, mixing sieves, with 75% ethanol wet granulation, drying, pack promptly.
Embodiment 2: Chinese medicinal composition capsules agent of the present invention
(1) Radix Angelicae Sinensis 80g is ground into impalpable powder, and is standby;
(2) Bulbus Fritillariae Cirrhosae 160g, Radix Glycyrrhizae 260g, Flos Carthami 180g, Radix Ginseng 80g, Radix Clematidis 180g, Radix Paeoniae Rubra 160g, Radix Adenophorae (Radix Glehniae) 210g, Radix Curcumae 130g, Rhizoma Pinelliae Preparatum 200g, Folium Nelumbinis Basis 160g, Rhizoma Polygonati Odorati 160g, Fructus Jujubae 210g, Radix Rehmanniae Preparata 160g decoct with water secondary, each 2 hours, filter merging filtrate, left standstill 48 hours, get supernatant, it is the thick paste of 1.20 (60 ℃) that concentrating under reduced pressure becomes relative density, adds above-mentioned fine powder, dry, be ground into fine powder, add dextrin 500g mixing, in the capsulae vacuus of packing into promptly.
Embodiment 3: Chinese medicine composition tablet of the present invention
(1) Radix Angelicae Sinensis 80g is ground into impalpable powder, and is standby;
(2) Bulbus Fritillariae Cirrhosae 160g, Radix Glycyrrhizae 260g, Flos Carthami 180g, Radix Ginseng 80g, Radix Clematidis 180g, Radix Paeoniae Rubra 160g, Radix Adenophorae (Radix Glehniae) 210g, Radix Curcumae 130g, Rhizoma Pinelliae Preparatum 200g, Folium Nelumbinis Basis 160g, Rhizoma Polygonati Odorati 160g, Fructus Jujubae 210g, Radix Rehmanniae Preparata 160g add 8 times of decoctings and boil secondary, each 2 hours, filter, merging filtrate, left standstill 48 hours, get supernatant, it is the thick paste of 1.20 (60 ℃) that concentrating under reduced pressure becomes relative density, adds above-mentioned fine powder and clear paste, drying, be ground into fine powder, add starch 300g, microcrystalline Cellulose 200g is with 70% ethanol wet granulation, tabletting, coating are promptly.

Claims (4)

1, a kind of Chinese medicine composition for the treatment of the esophageal carcinoma is to be made by effective ingredient and/or pharmaceutically acceptable carrier, it is characterized in that described effective ingredient is made by weight by following raw materials according:
Radix Ginseng 5-10 part Bulbus Fritillariae Cirrhosae 10-20 part Radix Clematidis 15-20 part
Radix Paeoniae Rubra 10-20 part Radix Adenophorae (Radix Glehniae) 15-25 part Radix Curcumae 10-15 part
Radix Glycyrrhizae 20-30 part Rhizoma Pinelliae Preparatum 15-25 part Folium Nelumbinis Basis 10-20 part
Flos Carthami 15-20 part Radix Angelicae Sinensis 5-10 part Rhizoma Polygonati Odorati 10-20 part
Fructus Jujubae 15-25 part Radix Rehmanniae Preparata 10-20 part.
2, Chinese medicine composition as claimed in claim 1 is characterized in that described effective ingredient made by weight by following raw materials according:
18 parts of 16 parts of Radix Clematidis of 8 parts of Bulbus Fritillariae Cirrhosae of Radix Ginseng
13 parts of 21 portions of Radix Curcumaes of 16 parts of Radix Adenophorae (Radix Glehniae) of Radix Paeoniae Rubra
16 parts of 20 parts of Folium Nelumbinis Basiss of 26 parts of Rhizoma Pinelliae Preparatum of Radix Glycyrrhizae
16 parts of 8 portions of Rhizoma Polygonati Odorati of 18 parts of Radix Angelicae Sinensis of Flos Carthami
16 parts in 21 parts of Radix Rehmanniaes Preparata of Fructus Jujubae.
3,, it is characterized in that described Chinese medicine composition can be made into granule, capsule and tablet as the arbitrary described Chinese medicine composition of claim 1-2.
4, a kind of preparation method as the arbitrary described Chinese medicine composition of claim 1-3 comprises the steps:
(1) Radix Angelicae Sinensis powder is broken into impalpable powder, and is standby;
(2) Bulbus Fritillariae Cirrhosae, Radix Glycyrrhizae, Flos Carthami, Radix Ginseng, Radix Clematidis, Radix Paeoniae Rubra, Radix Adenophorae (Radix Glehniae), Radix Curcumae, Rhizoma Pinelliae Preparatum, Folium Nelumbinis Basis, Rhizoma Polygonati Odorati, Fructus Jujubae, Radix Rehmanniae Preparata decoct with water secondary, each 2 hours, filter, merging filtrate left standstill 48 hours, get supernatant, it is the thick paste of 1.20 (60 ℃) that concentrating under reduced pressure becomes relative density, adds above-mentioned fine powder, drying, be ground into fine powder, make granule, capsule and tablet with pharmaceutically acceptable carrier.
CN 200810106125 2008-05-08 2008-05-08 Chinese medicinal composition for treating esophageal cancer and preparation thereof Pending CN101264301A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN 200810106125 CN101264301A (en) 2008-05-08 2008-05-08 Chinese medicinal composition for treating esophageal cancer and preparation thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN 200810106125 CN101264301A (en) 2008-05-08 2008-05-08 Chinese medicinal composition for treating esophageal cancer and preparation thereof

Publications (1)

Publication Number Publication Date
CN101264301A true CN101264301A (en) 2008-09-17

Family

ID=39987142

Family Applications (1)

Application Number Title Priority Date Filing Date
CN 200810106125 Pending CN101264301A (en) 2008-05-08 2008-05-08 Chinese medicinal composition for treating esophageal cancer and preparation thereof

Country Status (1)

Country Link
CN (1) CN101264301A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101773659A (en) * 2010-04-07 2010-07-14 泰一和浦(北京)中医药研究院有限公司 Chinese medicine composition for treating esophageal cancer and preparation method thereof
CN102935172A (en) * 2012-11-25 2013-02-20 董兴红 Traditional Chinese medicinal composition for treating achalasia of cardia
CN103071045A (en) * 2013-01-14 2013-05-01 顾燕君 Traditional Chinese medicine for treating esophageal achalasia

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101773659A (en) * 2010-04-07 2010-07-14 泰一和浦(北京)中医药研究院有限公司 Chinese medicine composition for treating esophageal cancer and preparation method thereof
CN101773659B (en) * 2010-04-07 2011-07-27 泰一和浦(北京)中医药研究院有限公司 Chinese medicine composition for treating esophageal cancer and preparation method thereof
CN102935172A (en) * 2012-11-25 2013-02-20 董兴红 Traditional Chinese medicinal composition for treating achalasia of cardia
CN102935172B (en) * 2012-11-25 2014-04-09 董兴红 Traditional Chinese medicinal composition for treating achalasia of cardia
CN103071045A (en) * 2013-01-14 2013-05-01 顾燕君 Traditional Chinese medicine for treating esophageal achalasia

Similar Documents

Publication Publication Date Title
CN102861298B (en) Traditional Chinese medicine composition for treating chronic gastritis
CN102078419B (en) Medicament for preventing and treating porcine reproductive and respiratory syndrome (PRRS) and preparation method thereof
CN103621989A (en) Dietary meal or meal replacement product for yin deficiency physique
CN101530563A (en) Traditional Chinese medicine composition for treating gastric ulcer and preparation method thereof
CN104069414A (en) Stomach-comforting pharmaceutical composition and application thereof
CN111481648A (en) Traditional Chinese medicine composition for tonifying spleen and nourishing stomach and traditional Chinese medicine preparation
CN101264301A (en) Chinese medicinal composition for treating esophageal cancer and preparation thereof
CN107095995B (en) A pharmaceutical composition for treating gastritis and gastric ulcer, and its preparation method
CN107913391B (en) Pharmaceutical composition for treating non-erosive gastroesophageal reflux disease and preparation method and application thereof
CN105028995A (en) Mixed dog food and preparation method thereof
CN100569263C (en) A kind of pharmaceutical composition for the treatment of stomachache and preparation method thereof
CN114306424B (en) Traditional Chinese medicine composition for treating obesity and preparation method and application thereof
CN101288756A (en) Chinese traditional medicine for treating chronic colitis
CN101647961A (en) Medicament for gastric cancer and esophagus cancer during postoperation and chemotherapy and preparation method thereof
CN103877483A (en) Traditional Chinese medicine for treating chronic gastritis and preparation method thereof
CN101632455A (en) Dendrobe film agent
CN103463449A (en) Traditional Chinese medicine composite used for treating haemorrhoids and preparation method and application thereof
CN105056170A (en) Application of traditional Chinese medicine composition in preparing drug for treating acute gastritis
CN101623488A (en) Chinese medicinal composition for treating panasthenia
CN101259205A (en) Medicaments assembly for treating adiposis and preparation thereof
CN103736045A (en) Traditional Chinese medicinal composition for treating superficial gastritis and preparation method thereof
WO2015149391A1 (en) Preparation of traditional chinese medicine for treating chronic enteritis and preparation method therefor
CN115845019B (en) Traditional Chinese medicine composition for preventing and treating porcine ileitis
CN103142883A (en) Traditional Chinese medicine composition for treating infantile diarrhea
CN116440221B (en) Compound weight-losing product containing white kidney beans and preparation method and application thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20080917